The Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial was funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
The SHOCK trial enrolled 302 heart attack patients with cardiogenic shock at 29 international sites. Investigators randomly assigned 152 patients to undergo either emergency angioplasty or bypass surgery (within 6 hours). Another 150 patients were assigned to receive intensive medical therapy including clot-busting drugs with possible revascularization after 54 hours.
"Early Revascularization and Long-term Survival in Cardiogenic Shock Complicating Acute Myocardial Infarction," by Judith Hochman, M.D. of the New York University School of Medicine, will be published in the June 7 issue of the Journal of the American Medical Association.
Who: Patrice Desvigne-Nickens, M.D., leader of NHLBI's Cardiovascular Medicine Scientific Research Group, is available to comment on the SHOCK study's findings. Dr. Desvigne-Nickens can discuss the importance of applying these findings to the treatment of cardiogenic shock, the leading cause of death in patients hospitalized for heart attack. As many as 43,000 hospitalized heart attack patients in the U.S. develop cardiogenic shock.
Contact: To schedule interviews, call the NHLBI Communications Office at (301) 496-4236.
Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at: www.nhlbi.nih.gov .
The National Institutes of Health (NIH) -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov .
JAMA